Molecure SA
WSE:MOC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.87
22
|
| Price Target |
|
We'll email you a reminder when the closing price reaches PLN.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Molecure SA
Income from Continuing Operations
Molecure SA
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Molecure SA
WSE:MOC
|
Income from Continuing Operations
-zł18.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
|
C
|
Celon Pharma SA
WSE:CLN
|
Income from Continuing Operations
-zł45.5m
|
CAGR 3-Years
-244%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Cannabis Poland SA
WSE:CBD
|
Income from Continuing Operations
-zł1.2m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
Molecure SA
Glance View
Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.
See Also
What is Molecure SA's Income from Continuing Operations?
Income from Continuing Operations
-18.3m
PLN
Based on the financial report for Dec 31, 2023, Molecure SA's Income from Continuing Operations amounts to -18.3m PLN.
What is Molecure SA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-33%
Over the last year, the Income from Continuing Operations growth was -20%.
You don't have any saved screeners yet
